BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35339898)

  • 1. Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach.
    Li X; Shong K; Kim W; Yuan M; Yang H; Sato Y; Kume H; Ogawa S; Turkez H; Shoaie S; Boren J; Nielsen J; Uhlen M; Zhang C; Mardinoglu A
    EBioMedicine; 2022 Apr; 78():103963. PubMed ID: 35339898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of estimated tumour purity on gene expression-based drug repositioning of Clear Cell Renal Cell Carcinoma samples.
    Koudijs KKM; Terwisscha van Scheltinga AGT; Böhringer S; Schimmel KJM; Guchelaar HJ
    Sci Rep; 2019 Feb; 9(1):2495. PubMed ID: 30792476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma.
    Luo Y; Shen D; Chen L; Wang G; Liu X; Qian K; Xiao Y; Wang X; Ju L
    Aging (Albany NY); 2019 Aug; 11(16):6029-6052. PubMed ID: 31422942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma.
    Yuan M; Shong K; Li X; Ashraf S; Shi M; Kim W; Nielsen J; Turkez H; Shoaie S; Uhlen M; Zhang C; Mardinoglu A
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression.
    Koudijs KKM; Terwisscha van Scheltinga AGT; Böhringer S; Schimmel KJM; Guchelaar HJ
    Sci Rep; 2018 Mar; 8(1):5250. PubMed ID: 29588458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
    Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
    BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Four Pathological Stage-Relevant Genes in Association with Progression and Prognosis in Clear Cell Renal Cell Carcinoma by Integrated Bioinformatics Analysis.
    Xu D; Xu Y; Lv Y; Wu F; Liu Y; Zhu M; Chen D; Bai B
    Biomed Res Int; 2020; 2020():2137319. PubMed ID: 32309427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Prognostic Related Hub Genes in Clear-Cell Renal Cell Carcinoma
    Jiang P; Sun TT; Chen CW; Huang RS; Zhong ZM; Lou XJ; Liu G; Wang L; Zuo RH
    Chin Med Sci J; 2021 Jun; 36(2):127-134. PubMed ID: 34231461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.
    Xu T; Ruan H; Song Z; Cao Q; Wang K; Bao L; Liu D; Tong J; Yang H; Chen K; Zhang X
    Biomed Pharmacother; 2019 Oct; 118():109264. PubMed ID: 31390578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of drug targets and therapeutic agents based on drug repositioning to treat lung adenocarcinoma.
    Graves OK; Kim W; Özcan M; Ashraf S; Turkez H; Yuan M; Zhang C; Mardinoglu A; Li X
    Biomed Pharmacother; 2023 May; 161():114486. PubMed ID: 36906970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Analysis of Three Publicly Available Gene Expression Profiles Identified Genes and Pathways Associated with Clear Cell Renal Cell Carcinoma.
    Han Y; Wang L; Wang Y
    Med Sci Monit; 2020 Jul; 26():e919965. PubMed ID: 32712616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of EGFR as a Novel Key Gene in Clear Cell Renal Cell Carcinoma (ccRCC) through Bioinformatics Analysis and Meta-Analysis.
    Wang S; Yu ZH; Chai KQ
    Biomed Res Int; 2019; 2019():6480865. PubMed ID: 30895194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systems biology based drug repositioning for development of cancer therapy.
    Turanli B; Altay O; Borén J; Turkez H; Nielsen J; Uhlen M; Arga KY; Mardinoglu A
    Semin Cancer Biol; 2021 Jan; 68():47-58. PubMed ID: 31568815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal Identification of Dysregulated Genes and Pathways in Clear Cell Renal Cell Carcinoma Based on Systematic Tracking of Disrupted Modules.
    Wang SM; Sun ZQ; Li HY; Wang J; Liu QY
    Comput Math Methods Med; 2015; 2015():313740. PubMed ID: 26543493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
    Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
    J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma.
    Yoshino H; Yamada Y; Enokida H; Osako Y; Tsuruda M; Kuroshima K; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M
    PLoS One; 2020; 15(7):e0236119. PubMed ID: 32667929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis.
    MotieGhader H; Tabrizi-Nezhadi P; Deldar Abad Paskeh M; Baradaran B; Mokhtarzadeh A; Hashemi M; Lanjanian H; Jazayeri SM; Maleki M; Khodadadi E; Nematzadeh S; Kiani F; Maghsoudloo M; Masoudi-Nejad A
    Sci Rep; 2022 Jun; 12(1):9417. PubMed ID: 35676421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fifteen hub genes associated with progression and prognosis of clear cell renal cell carcinoma identified by coexpression analysis.
    Wang Y; Chen L; Wang G; Cheng S; Qian K; Liu X; Wu CL; Xiao Y; Wang X
    J Cell Physiol; 2019 Jul; 234(7):10225-10237. PubMed ID: 30417363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
    Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
    Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients.
    Bayraktar A; Li X; Kim W; Zhang C; Turkez H; Shoaie S; Mardinoglu A
    J Transl Med; 2023 May; 21(1):332. PubMed ID: 37210557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.